Breast MRI: Fundamentals and technical aspects

Breast MRI: Fundamentals and Technical Aspects

Volumn , Issue , 2008, Pages 1-251

  Hendrick, R Edward ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84895336758     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-0-387-73507-8     Document Type: Book

References (215)

1. Haacke EM, Brown RW, Thompson MR, et al. Magnetic Resonance Imaging: Physical Principles and Sequence Design. New York: John Wiley & Sons, 1999.
2. Hendrick RE. Physics and technical aspects of breast MRI. In "Categorical Course in Diagnostic Radiology Physics: Advances in Breast Imaging-Physics, Technology, and Clinical Applications." Oak Brook, IL: RSNA Publications, 2004, p. 259-278.
3. rd Edition. New York: C.V. Mosby Publishing Co, 1999, especially Ch 1-14.
4. Markisz JA, Aquilia MG. Technical magnetic resonance imaging. Stamford, CT: Appleton & Lange, 1999.
5. Morris EA, Liberman L. Breast MRI: Diagnosis and Intervention. New York: Springer, 2005.
6. Warren R, Coulthard A, eds. Breast MRI in practice. London: Martin Dunitz, 2002.
7. Fischer U. Practical MR Mammography. Stuttgart: Thieme Publishing Co, 2004.
8. Heywang-Kobrunner SH, Dershaw DD, Schreer I. Diagnostic Breast Imaging. Stuttgart, New York: Thieme Publishing Co., 2001.
9. Morris EA. Breast cancer imaging with MRI. Radiol Clin North Am 2002; 40: 443-466.
10. Orel SG, Schnall MD. MR imaging of the breast for the detection, diagnosis, and staging of breast cancer. Radiology 2001; 220: 13-30
11. Schnall MD. Breast imaging technology: Application of magnetic resonance imaging to early detection of breast cancer. Breast Cancer Res. 2001, 3: 17-21
12. Weinreb JC, Newstead G. MR imaging of the breast. Radiology 1995; 196: 593-610.
13. Kuhl CF, ed. Breast MR imaging. Magnetic Resonance Imaging Clinics. London: Elsivier Saunders, 2006; 14: 293-430.
14. Hendrick RE, Osborn A, Kanal E. Basic MRI physics. In Kressel H, Modic M, Murphy W. Syllabus: Special Course-MR 1990. Chicago: RSNA Publications, 1990, p. 7-30.
15. Rabi, I. I., Zacharias, J. R., Millman, S. and Kusch, P. A new method of measuring nuclear magnetic moment. Physical Review 1938; 53, 318-323.
16. Purcell EM, Torrey HC, Pound RV. Resonance absorption by nuclear magnetic moments in a solid. Phys. Rev. 1946; 69, 37-38.
17. Bloch F, Hansen WW, Packard M. Nuclear induction. Phys. Rev. 1946; 69, 127.
18. Bloch F, Hansen WW. Packard ME. Nuclear induction. Phys Rev. 1946; 69: 127-129.
19. Purcell EM, Torrey HC, Pound RV. Resonance absorption by nuclear magnetic moments in a solid. Phys Rev. 1946; 69: 37-38.
20. Damadian R. Tumor detection by nuclear magnetic resonance. Science 1971; 171: 1151-1153.
21. rd Edition. New York: C.V. Mosby Publishing Co, 1999; Vo l 1, pp 33-42.
22. Hendrick RE, Haacke EM. Basic physics of MR contrast agents and maximization of image contrast. J. Magn. Reson. Imaging 1993; 3: 137-148.
23. Padhani AR. Contrast agent dynamics in breast MRI. In Warren R, Coulthard A, eds. Breast MRI in practice. London: Martin Dunitz, 2002. p. 43-52.
24. Lauterbur PC. Image formation by induced local interactions: examples employing nuclear magnetic resonance," Nature 1973; 242: 190-191.
25. Hendrick RE, Osborn A, Kanal E. Basic MRI physics. In Kressel H, Modic M, Murphy W. Syllabus: Special Course-MR 1990. RSNA Publications, Chicago, IL, 1990, pp. 7-30.
26. rd Edition. Eds DD Stark and WG Bradley. St. Louis: Mosby Publishing Co., 1999. Volume 1, Ch. 2, p. 15-32.
27. rd Edition. Eds DD Stark and WG Bradley. St. Louis: Mosby Publishing Co., 1999. Volume 1, Ch. 1, p. 1-14.
28. rd Edition. St. Louis: Mosby Publishing Co., 1999, Vo l 1, Ch 4, 43-68.
29. Sachs TS, Meyer CH, Hu BS, et al. Real-time motion detection in spiral MRI using navigators. Magn Reson Med. 1994; 32: 639-45.
30. rd Edition. St. Louis: Mosby Publishing Co., 1999, Vo l 1, Ch 6, 87-124.
31. Perman WH, Heiberg E V, Herrmann VM. Half-Fourier, three-dimensional technique for dynamic contrast-enhanced MR imaging of both breasts and axillae: initial characterization of breast lesions. Radiology 1996; 200: 263-269.
32. rd Edition St. Louis: Mosby Publishing Co. Volume 1, pp 43-68.
33. Hahn EL (1950) Spin echoes. Physical Review 80: 580.
34. Haacke EM, Brown RW, Thompson MR, et al. (1999) Magnetic Resonance Imaging: Physical Principles and Sequence Design. New York: John Wiley & Sons, especially Ch 8, p 118-129.
35. Crooks L, Hoenninger J, Arakawa M, et al. High resolution magnetic resonance imaging: technical concepts and their implementation. Radiology 1984; 150; 163-171.
36. Haase A, Frahm J, Matthaei D, et al. Regional physiological functions depicted by sequences of rapid magnetic resonance images. Lancet 1985; 2: 893.
37. Haase A, Frahm J, Matthaei D, et al. FLASH imaging. Rapid NMR imaging using low flip-angle pulses. J Magn Reson 1986; 67: 258-266.
38. Frahm J, Haase A, Matthaei D. Rapid NMR imaging of dynamic processes using the FLASH technique. Magn. Reson. Med 1986; 3: 321-327.
39. Haase A, Matthaei D, Hanicke W, et al. Dynamic digital subtraction MR imaging using the FLASH method. Radiology 1986; 160: 537-541.
40. Frahm J, Haase A, Matthaei D, et al. Rapid three dimensional MR imaging using the FLASH technique. J Comput. Assist. Tomogr. 1986; 10: 363-368.
41. Haacke EM, Tkach JA. Fast MR imaging: techniques and clinical applications. American Journal of Roentgenology 1990; 155: 951-964.
42. rd Edition. St. Louis: Mosby Publishing Co., 1999, Vo l 1, Ch. 4, p. 43-68.
43. rd edition. New York: C.V. Mosby Publishing, 1999:87-124.
44. Haacke EM, Brown RW, Thompson MR, et al. Magnetic Resonance Imaging: Physical Principles and Sequence Design. Ch 18. New York: John Wiley & Sons, 1999: 451-512.
45. Harms SE, Flamig DP, Hensley KL, et al. MR imaging of the breast with rotating delivery of excitation off-resonance: clinical experience with pathologic correlation. Radiology 1993; 187:493-501.
46. Heywang SH, Wolf A, Pruss E, et al. MR imaging of the breast with Gd-DTPA: use and limitations. Radiology 1989; 171:95-103.
47. Hennig J, Nauerth A, Friedburg H. RARE imaging: a fast imaging method for clinical MR. Mag. Reson. Med. 1986; 3: 823-833.
48. rd Edition. St. Louis: Mosby Publishing Co., Vo l 1, Ch 7, 1999; 125-157.
49. Mansfield P. Multi-planar image formation using NMR spin echoes. J. Phys. Chem. 1977; 10: L55-L58.
50. Smith FW, JR Mallard, Reid A, et al. Nuclear magnetic resonance tomographic imaging in liver disease. Lancet 1981; 1: 963-966.
51. rd Edition. St. Louis: C.V. Mosby Publishing Co. 1999, Vol 1, Ch 5, 69-86.
52. rd Edition. St. Louis: Mosby Publishing Co., 1999, Vo l 1, Ch 4, p. 43-68.
53. Haacke EM, Brown RW, Thompson MR, et al. Magnetic Resonance Imaging: Physical Principles and Sequence Design. New York: John Wiley & Sons, 1999, especially Ch. 19,; 513-568.
54. Les Prix Nobel. The Nobel Prizes 2003, Editor: Tore Frängsmyr, [Nobel Foundation], Stockholm, 2004. Found on the Internet at: http://nobelprize.org/nobel-prizes/medicine/laureates/2003/mansfield-autobio. html (last accessed September 25, 2006).
55. rd Edition, St. Louis: Mosby Publishing Co., 1999, Vo l 1, Ch. 4, p. 43-68.
56. Edelstein WA, Glover GH, Hardy CJ, Redington RW. The intrinsic signal-to-noise ratio in NMR imaging. Magn. Reson. Med. 1986; 3: 604-618.
57. Haacke EM, Brown RW, Thompson MR, et al. Magnetic Resonance Imaging: Physical Principles and Sequence Design. New York: John Wiley & Sons, 1999, especially Ch 15, 331-380.
58. Henkelman RM. Measurement of signal intensities in the presence of noise in MR images. Med. Phys.1985; 12: 232-233.
59. Rose A. Vision: human and electronic. New York: Plenum Press, 1973.
60. Ross RJ, Thompson JS, Kim K, et al. Nuclear magnetic resonance imaging and evaluation of human breast tissue: preliminary clinical trials. Radiology 1982; 143: 195-205.
61. El Yousef SJ, Alfidi RJ, Duchesnau RH, et al. Initial experience with nuclear magnetic resonance (NMR) imaging of the human breast, J Comput Assist Tomogr. 1983; 7: 215.
62. McSweeney MB, Small WC, Cerny V, et al. Magnetic resonance imaging in the diagnosis of breast disease: use of transverse relaxation times. Radiology 1984; 153: 741-744.
63. Wiener JI, Chako AC, Merten CW, et al. Breast and axillary tissue MR imaging: correlations of signal intensities and relaxation times with pathologic findings, Radiology 1986; 160: 299-305.
64. Merchant TE, Thelissen GRP, de Graaf PW, et al. Application of a mixed imaging sequence for MR imaging characterization of human breast disease. Acta Radiol 1993; 34: 356-361.
65. Heywang SH, Hahn D, Schmid H, et al. MR imaging of the breast using gadolinium-DTPA. J. Comput. Assist. Tomogr. 1986; 10: 199-204.
66. The labeling information of each FDA-approved Gd-based contrast agent was consulted for the data in this section: Magnevist, Document NDA 19-596/S-033, available at: http://www.fda.gov/cder/foi/label/2005/19596s033lbl.pdf, last accessed: 5-17-07
67. Berlex Imaging, 2004; Prohance, Document F1/3.5281.96, Bracco Diagnostics, Revised April 2006, available at: http://dailymed. nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?id=1069&type=display, last accessed 6-17-07.
68. Multihance, Document F1/3.5410.37, Bracco Diagnostics, revised January 2005, available at: http://www.bracco.com/NR/rdonlyres/B78D4E76-2E3D-4C88-81A7- C8C5B875DD28/0/MULTIHANCEPIJan2005.pdf, last accessed on 6-17-07;
69. Optimark, Document NDA 20-937/20-975/20-976/S-009 Mallinckrodt Inc, Revised January 2003, available at: http://www.fda.gov/cder/foi/label/2006/ 020937,020975,020976s009lbl.pdf, last accessed on 6-17-07;
70. Omniscan, ONC-2P-OSLO, GE Healthcare, October 2005, revised March 2007, available at: http://dailymed.nlm. nih.gov/dailymed/drugInfo.cfm?id=3425, last accessed on 6-17-07.
71. Hendrick RE, Haacke EM. Basic physics of MR contrast agents and maximization of image contrast. J. Magn. Reson. Imaging 1993; 3: 137-148.
72. Cavagna FM, Maggioni F, Castelli PM, et al. Gadolinium chelates with weak binding to serum proteins: a new class of high-efficiency general purpose contrast agents for magnetic resonance imaging. Invest. Radiol. 1997; 32: 780-796.
73. Kirchin MA, Pirovano G, Spinazzi A. Gadobenate dimeglumine (Gd-BOPTA): an overview. Invest. Radiol. 1998; 33: 798-809.
74. Spinazzi A, Lorusso V, Pirovano G, et al. Safety, tolerance, biodistribution and MR imaging enhancement of the liver with gadobenate dimeglumine. Acad. Radiol. 1999; 6: 282-291.
75. Knopp MV, Bourne MW, Sardanelli F, et al. Gadobenate dimeglumine-enhanced MRI of the breast: analysis of dose response and comparison with gadopentetate dimeglumine. AJR 2003; 181: 663-676.
76. Pediconi F, Catalano C, Occhiato R, et al. Breast lesion detection and characterization at contrast-enhanced MR mammography: Gadobenate dimeglumine versus gadopentetate digeglumine. Radiology 2005; 237: 45-56.
77. Runge VM, Armstrong MR, Barr RG, et al. A clinical comparison of the safety and efficacy of MultiHance (gadobenate dimeglumine) and Omniscan (gadodiamide) in magnetic resonance imaging in patients with central nervous system pathology. Invest Radiol 2001;36:65-71.
78. Knopp M V, Weiss E, Sinn HP, et al. Pathophysiologic basis of contrast enhancement in breast tumours. J. Magn. Reson. Imaging 1999; 10: 260-266.
79. Weind KL, Maier CF, Rutt BK, et al. Invasive carcinomas and fibroadenomas of the breast: comparison of microvessel distributions-implications for imaging modalities. Radiology 1998; 208: 477-483.
80. Shellock FG, Kanal E. Safety of magnetic resonance imaging contrast agents. J Magn Reson Imaging 1999; 19: 477-484.
81. Remy-Jardin M, Dequiedt P, Ertzbischoff O, et al. Safety and effectiveness of gadolinium-enhanced multi-detector row spiral CT angiography of the chest: preliminary results in 37 patients with contraindications to iodinated contrast agents. Radiology 2005; 235: 819-826.
82. Becker J, Thompson H. Renal safety of gadolinium-based contrast agent for ionizing radiation imaging (Letter to the editor). Radiology 2006; 240: 301-302.
83. Kuo PH, Kanal E, Abu-Alfa AK, Cowper SE. Gadolinium-based MR contrast agents and nephrogenic systemic fibrosis. Radiology 2007; 242: 647-649.
84. U.S. FDA Public Health Advisory: Information for Healthcare Professionals: Gadolinium-based Contrast Agents for Magnetic Resonance Imaging. Published on-line May 23, 2007 at: http://www.fda.gov/cder/drug/infopage/gcca/ default.htm or http://www.fda.gov/cder/drug/InfoSheets/HCP/gcca-200705HCP.pdf. Last accessed on June 17, 2007.
85. Broome DR, Girguis MS, Baron PW, et al. Gadodiamide-associated Nephrogenic Systemic Fibrosis: why radiologists should be concerned. Am. J. Roentgenol., 2007; 188: 586-592.
86. Kriege M, Brekelmans CT, Boetes C, et al. Efficacy of MRI and mammography for breast-cancer screening in women with a familial or genetic predisposition. N Engl J Med. 2004; 351: 427-437.
87. Kuhl CK, Schrading S, Leutner CC, et al. Mammography, breast ultrasound, and magnetic resonance imaging for surveillance of women at high familial risk for breast cancer. J Clin Oncol 2005; 23: 8469-8476.
88. Tilanus-Linthorst MM, Obdeijn IM, Bartels KC. MARIBS study. Lancet. 2005; 366: 291-292.
89. Stoutjesdijk MJ, Boetes C, Jager GJ, et al. Magnetic resonance imaging and mammography in women with a hereditary risk of breast cancer. J Natl Cancer Inst. 2001; 93: 1095-102.
90. Warner E, Plewes DB, Hill KA, et al. Surveillance of BRCA1 and BRCA2 mutation carriers with magnetic resonance imaging, ultrasound, mammography, and clinical breast examination. JAMA. 2004; 292: 1317-1325.
91. Morris EA, Liberman L, Ballon DJ, et al. MRI of occult breast carcinoma in a high-risk population. AJR 2003; 181: 619-626.
92. Heywang-Kobrunner SH, Haustein J, Pohl C. Contrast-enhanced MR imaging of the breast: comparison of two different doses of gadopentetate dimeglumine. Radiology 1994; 191, 639-646.
93. Joe BN, Bae KT, Chen VY, et al. Dynamic MR contrast enhancement characteristics of breast cancer: effect of contrast injection rate (Abstract). Radiology 2003; RSNA Annual Meeting Abstracts, p. 289.
94. Kuhl CK, Peter Mielcareck P, Klaschik S, et al. Dynamic breast MR imaging: are signal intensity time course data useful for differential diagnosis of enhancing lesions? Radiology 1999; 211: 101-110.
95. Liney GP, Gibbs P, Hayes C, et al. Dynamic contrast-enhanced MRI in the differentiation of breast tumors: user-defined versus semi-automated region-of-interest analysis. J Magn Reson Imaging 1999; 10: 945-949.
96. Harms SE, Flamig DP, Hensley KL, et al. MR imaging of the breast with rotating delivery of excitation off-resonance: clinical experience with pathologic correlation. Radiology 1993; 187: 493-501.
97. Kuhl CK, Schild HH, Morakkabati N. Dynamic bilateral contrast-enhanced MR imaging of the breast: trade-off between spatial and temporal resolution. Radiology 2005; 236: 789-800.
98. Zeppa R. Vascular response of the breast to estrogen. J. Clin. Endocrinol. Metab. 1969; 29: 695-700.
99. Kuhl CK, Bieling HB, Gieseke J, et al. Healthy premenopausal breast parenchyma in dynamic contrast-enhanced MR imaging of the breast: normal contrast medium enhancement and cyclical phase dependency. Radiology 1997; 203: 137-144.
100. Muller-Schimpfle M, Ohmenhauser MD, Stoll P, et al. Menstrual cycle and age: influence on parenchymal contrast medium enhancement in MR imaging of the breast. Radiology 1997; 203: 145-149.
101. Padhani AR. (2002) Contrast agent dynamics in breast MRI. In Warren R, Coulthard A, eds. Breast MRI in practice London: Martin Dunitz, pp. 43-52.
102. Brinck U. (2004) Tumor angiogenesis. In Fischer U. (2004) Practical MR Mammography. Stuttgart: Thieme Publishing Co., p 22.
103. Brinck U. (2004) Tumor angiogenesis and MR mammography. In Fischer U. (2004) Practical MR Mammography. Stuttgart: Thieme Publishing Co., p 23.
104. rd Edition. New York: C.V. Mosby Publishing Co, Vol 1, pp 33-42.
105. rd Edition. New York: C.V. Mosby Publishing Co, Vol 1, Ch 12, pp 257-276.
106. rd Edition. New York: C.V. Mosby Publishing Co, Vol 1, Ch 15, pp 307-320.
107. Heywang SH, Hahn D, Schmidt H, et al. MR imaging of the breast using Gd-DTPA. J. Comput. Assist. Tomogr. 1986; 10: 615-620.
108. Heywang SH, Bassermann R, Fenzl G, et al. MRI of the breast: histopathologic correlation. Eur J Radiol 1987; 7: 175-182.
109. Heywang-Koebrunner SH, Haustein J, Pohl C, et al. Contrast-enhanced MRI of the breast: comparison of two dosages. Radiology 1994; 191: 639-646.
110. rd Edition. St. Louis: C. V. Mosby Publishing Co., 1999, 257-275.
111. Harms SE, Flamig DP, Hensley KL, et al. MR imaging of the breast with rotating delivery of excitation off-resonance: clinical experience with pathologic correlation. Radiology 1993; 187: 493-501.
112. rd Edition. St. Louis: C.V. Mosby Publishing Co., 1999; 321-333.
113. Bootes C, Barentsz JO, Mus RD, et al. MR characterization of suspicious breast lesions with a gadolinium-enhanced turbo-FLASH subtraction technique. Radiology 1994; 193: 777-781.
114. Kuhl CK, Mielcarek P, Klaschik S, et al. Dynamic breast MR imaging: are signal intensity time course data useful for differential diagnosis of enhancing lesions? Radiology 1999; 211: 101-110.
115. Edelstein WA, Glover GH, Hardy CJ, et al. The intrinsic signal-to-noise ratio in NMR imaging. Magn. Reson. Med. 1986; 3: 604-618.
116. Haacke EM, Brown RW, Thompson MR, et al Magnetic Resonance Imaging: Physical Principles and Sequence Design. New York: John Wiley & Sons, 1999, p. 378.
117. Friedman PD, Swaminathan S V, Herman K, et al. Breast MRI: the importance of bilateral imaging. AJR 2006; 187: 345-349.
118. Mahfouz AE, Sherif H, Saad A, et al. Gadolinium-enhanced MR angiography of the breast: is breast cancer associated with ipsilateral higher vascularity. Eur Radiol 2001; 11: 965-969.
119. Sardanelli F, Iozzelli A, Fausto A, et al. Gadobenate dimeglumine-enhanced MR imaging breast vascular maps: association between invasive cancer and ipsilateral increased vascularity. Radiology 2005; 235: 791-797.
120. Fischer U, Kopka L, Grabbe E. Breast carcinoma: effect of preoperative contrast-enhanced MR imaging on the therapeutic approach. Radiology 1999; 213; 881-888.
121. Liberman L, Morris EA, Kim CM, et al. MR imaging findings in the contralateral breast of women with recently diagnosed breast cancer. Am. J. Roentgenol., 2003; 180: 333-341.
122. Lee, S.G., et al., MR imaging screening of the contralateral breast in patients with newly diagnosed breast cancer: preliminary results. Radiology, 2003. 226(3): p. 773-8.
123. Lehman, C.D., et al., Added cancer yield of MRI in screening the contralateral breast of women recently diagnosed with breast cancer: results from the International Breast Magnetic Resonance Consortium (IBMC) trial. J Surg Oncol, 2005. 92(1): p. 9-15; discussion 15-6.
124. Slanetz, P.J., et al., Occult contralateral breast carcinoma incidentally detected by breast magnetic resonance imaging. Breast J, 2002. 8(3): p. 145-8.
125. Viehweg, P., et al., MR imaging of the contralateral breast in patients after breast-conserving therapy. Eur Radiol, 2004. 14(3): p. 402-8.
126. Lehman CD, Gatsonis C, Kuhl CK, Hendrick RE, Pisano ED, et al. MRI evaluation of the contralateral breast in women with recently diagnosed breast cancer. N Engl J Med 2007; 356:1295-1303.
127. Dietrich O, Nikolaou K, Wintersperger BJ, et al. iPAT: Application for fast and cardiovascular MR imaging. Electromedica 2002; 70: 133-145.
128. Glockner JF, Houchun HH, Stanley DW, et al. Parallel imaging: a user's guide. Radiographics 2005; 25: 1279-1297.
129. Hendrick RE, Haake EM. Basic physics of contrast agents and maximization of image contrast. J. Magn. Reson. Imaging 1993; 3: 137-148.
130. rd ed. St. Louis: C.V. Mosby Publishing Co., 1999; 87-124.
131. Rausch D, Hendrick RE. How to optimize clinical breast MR imaging practices and techniques on your 1.5 T system. RadioGraphics 2006; 26:1469-1484.
132. Kuhl CK, Schild HH, Morakkabati N. Dynamic bilateral contrast-enhanced MR imaging of the breast: trade-off between spatial and temporal resolution. Radiology 2005; 236: 789-800.
133. Perman WH, Heiberg E V, Herrmann VM. Half-Fourier, three-dimensional technique for dynamic contrast-enhanced MR imaging of both breasts and axillae: initial characterization of breast lesions. Radiology 1996; 200: 263-269.
134. rd edition. New York: C.V. Mosby Publishing, 1999: 87-124.
135. Hutchinson M, Raff U. Fast MRI data acquisition using multiple detectors. Magn. Reson. Med. 1988; 6: 87-91.
136. Carlson JW, Minemura T. Imaging time reduction through multiple receiver coil data acquisition and image reconstruction. Magn. Reson. Med. 1993; 29: 681-687.
137. Pruessmann KP, Weiger M, Scheidegger MP, et al. SENSE: sensitivity encoding for fast MRI. Magn. Reson. Med. 1999; 42: 952-962.
138. Deurloo EE, Muller SH, Peterse JL, et al. Clinically and mammographically occult breast lesions on MR images: potential effect of computerized assessment on clinical reading. Radiology 2005; 234: 693-701.
139. DeMartini W, Lehman C, Peacock S, et al. Computer-aided detection applied to breast MRI: assessment of CAD-generated enhancement and tumor sizes in breast cancers before and after neoadjuvant chemotherapy. Academic Radiology 2006; 12: 806-814.
140. Mitchell D. Schnall MD, Blume J, Bluemke DA, et al. Diagnostic architectural and dynamic features at breast MR imaging: multicenter study. Radiology 2006; 238: 42-53.
141. Mahfouz AE, Sherif H, Saad A, et al. Gadolinium-enhanced MR angiography of the breast: is breast cancer associated with ipsilateral higher vascularity. Eur Radiol 2001; 11: 965-969.
142. Sardanelli F, Iozzelli A, Fausto A, et al. Gadobenate dimeglumine-enhanced MR imaging breast vascular maps: association between invasive cancer and ipsilateral increased vascularity. Radiology 2005; 235: 791-797.
143. Kuhl CK, Peter Mielcareck P, Klaschik S, et al. Dynamic breast MR imaging: are signal intensity time course data useful for differential diagnosis of enhancing lesions? Radiology 1999; 211: 101-110.
144. th Scientific Assembly and Annual Meeting, p. 289, Chicago, IL, December 2003.
145. ™) improve interobserver variability in breast MRI contrast kinetic analysis: a comparison study between automated and manual ROI determination. (Abstract). The Radiological Society of North America 91st Scientific Assembly and Annual Meeting, Chicago, IL November 30, 2005.
146. Hendrick RE, Russ PD, Simon J. MRI: Principles and Artifacts, Raven Press, 1993.
147. rd Edition, 1999. St. Louis: Mosby Publishing Co., Vol 1, Ch. 10, p. 215-230.
148. Pattany PM, Phillips J, Chiu LC, et al. Motion artifact suppression technique (MAST) for MR Imaging. J. Comput. Assist. Tomogr. 1987; 11: 369-377.
149. Purcell EM. Electricity and magnetism. Berkeley Physics Course-Volume 2. New York: McGraw-Hill Book Co. 1965, p. 394-399.
150. Berg W, Birdwell R. Diagnostic Imaging: Breast, Salt Lake City: Amirsys, Inc. 2006, p. IV-7-18 to 23.
151. Genson CC, Blane CE, Helvie MA, et al. Effects on breast MRI of artifacts caused by metallic tissue marker clips. AJR 2007; 188: 372-376.
152. Chen X, Lehman CD, Dee KE. MRI-guided breast biopsy: clinical experience with 14-gauge stainless steel core biopsy needle. AJR 2004; 182:1075-1080.
153. Harvey JH, Hendrick RE, Coll J, et.al. Breast MR imaging artifacts: how to recognize and fix them. Radiographics, to be published November/December 2007.
154. Shellock FG, Crues JV. MR procedures: biologic effects, safety, and patient care. Radiology, 2004;232:635-652.
155. Shellock FG. Magnetic Resonance Procedures. Health Effects and Safety. CRC Press, Boca Raton, FL, 2001.
156. Kanal E, Barkovich AJ, Bell C, et al. ACR Guidance Document for Safe MR Practices: 2007. Am. J. of Roentgenology 2007; 188: 1-27.
157. Radiology Websites: MRI Safety Websites: http://www.refindia.net/rlinks/ reviewedlinks/MRI-safety.htm, last accessed 2/1/07.
158. Shellock FG. http://www.mrisafety.com/is an invaluable website for MRI safety, last accessed 2/1/07.
159. Shellock FG. Reference Manual for Magnetic Resonance Safety and Implants: 2007 Edition. Biomedical Research Publishing Group, Los Angeles, CA, 2007.
160. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Devices and Radiological Health, Guidance for Industry and FDA Staff. Criteria for Significant Risk Investigations of Magnetic Resonance Diagnostic Devices, July 14, 2003.
161. Schenck JF. Health effects and safety of static magnetic fields. In: Shellock FG, ed. Magnetic resonance procedures: health effects and safety. Boca Raton, FL: CRC Press, 2001; pp. 1-30.
162. Schenck JF. Safety of strong, static magnetic fields. J Magn Reson Imaging 2000; 12; 2-19.
163. Schenck JF, Dumoulin CL, Redington RW, Kressel HY, Elliott RT, McDougall IL. Human exposure to 4.0-Tesla magnetic fields in a whole-body scanner. Medical Physics 1992; 19: 1089-1098.
164. Shellock FG. Bioeffects of gradient magnetic fields. Available at http://www.mrisafety.com/, last accessed 2/1/07.
165. Abart J, Eberhardt K, Fischer H, et al. Peripheral nerve stimulation by time-varying magnetic fields. J Comput Assis Tomogr 1997; 21: 532-538.
166. Bourland JD, Nyenhuis JA, Schaefer DJ. Physiologic effects of intense MRI gradient fields. Neuroimaging Clin North Am 1999; 9: 363-377.
167. Schaefer DJ, Bourland JD, Nyenhuis JA. Review of patient safety in time-varying gradient fields. J Magn Reson Imaging 2000; 12: 20-29.
168. FDA (USDHHS), Center for Devices and Radiologic Health, Office of Device Evaluation, Division of Reproductive, Abdominal, Ear, Nose, Throat and Radiological Devices, Computed Image Device Branch, 1997 (http://www.fda.gov/ cdrh/ude/magdev.html).
169. Brummett RE, Talbot JM, Charuhas P. Potential hearing loss resulting from MR imaging. Radiology 1988; 169: 539-540.
170. Shellock FG, Kanal E. Policies, guidelines, and recommendations for MR imaging safety and patient management. J. Magn. Reson. Imaging 1991; 1: 97-101.
171. Kanal E, Gillen J, Evans JA, et al. Survey of reproductive health among female MR workers. Radiology 1993; 187: 395-399.
172. Hoult DL, Richards RE. The signal-to-noise ratio of the nuclear magnetic resonance experiment. J. Magn. Res. 1976; 24: 71-85.
173. Edelstein WA, Glover GH, Hardy CJ, Redington RW. (1986) The intrinsic signal-to-noise ratio in NMR imaging. Magn. Reson. Med. 3: 604-618.
174. Haacke EM, Brown RW, Thompson MR, et al. Magnetic Resonance Imaging: Physical Principles and Sequence Design. New York: John Wiley & Sons, 1999, especially Ch. 15, 331-380.
175. Kuhl CK, Jost P, Morakkabati N, et al. Contrast-enhanced MR imaging of the breast at 3.0 and 1.5 T in the same patients: Initial Experience. Radiology 2006 239: 666-676.
176. Daniel BL, Yen YF, Glover GH, et al. Breast disease: dynamic spiral MR imaging Radiology 1998; 209: 499.
177. Harms SE, Flamig DP, Hensley KL, et al. MR imaging of the breast with rotating delivery of excitation off-resonance: clinical experience with pathologic correlation. Radiology 1993; 187: 493-501.
178. Causer PA, Piron CA, Jong RA, et al. MR imaging-guided breast localization system with medial or lateral access. Radiology 2006; 240: 369-379.
179. Le Bihan D, et al. Diffusion MR imaging: clinical application. Am. J. Roentgenol. 1992; 159: 591-599.
180. Sinha S, Sinha U. Functional magnetic resonance of human breast tumors: diffusion and per-fusion imaging. Annals New York Academy of Sciences 95-115.
181. rd Edition.St. Louis: C.V. Mosby Publishing Co., 1999; 125-157.
182. Sinah S, Lucas-Quesada FA, Sinha U, et al. In-vivo diffusion-weighted MRI of the breast: potential for lesion characterization. J. Magn. Reson. Imaging 2002; 15: 693-704.
183. Detre JA et al. Tissue specific perfusion imaging using arterial spin labeling. NMR Biomed. 1994; 7: 75-82.
184. Tofts PS. Modeling tracer kinetics in dynamic Gd-DTPA MR imaging. J. Magn. Reson. Imaging 1997; 7: 91-101.
185. Roberts HC, Roberts TPL, Brasch RC, et al. Quantitative measurement of microvacular permeability in human brain tumors achieved using dynamic contrast enhanced MR imaging: correlation with histologic grade. Am. J. Neuroradiol. 2000; 21: 891-899.
186. &z.ast; susceptibility-contrast. First-pass perfusion MR imaging. Radiology 1997; 202: 87-95.
187. Helbich T, Roberts TPL, Grossman A, et al. MR imaging of breast tumors: testing of different analytic methods with gadopentetate (abstract). Eur. Radiol. 1999; 9 (suppl 1): 410.
188. &z.ast;-weighted first pass perfusion imaging. Radiology 2000; 216: 545-553.
189. DeLille J, PJ Slanetz, ED Yeh, et al. Breast cancer: regional blood flow and blood volume measured with magnetic susceptibility-based MR imaging-initial results. Radiology 2002; 223: 558-565.
190. 1H NMR spectroscopic characterization of perchloric acid extracts from breast carcinomas and non-involved breast tissue. NMR Biomed. 1994; 7: 181-194.
191. Nagandank W. Studies of human tumors by MRS. A review. NMR Biomed 1992; 5: 303-324.
192. Podo F. Tumour phospholipids metabolism. NMR Biomed. 1999; 12: 413-439.
193. Aboagye EO, Bhujwalla ZM. Malignant transformation alters membrane choline phospholipids metabolism of human mammary epithelial cells. Cancer Research 1999; 59: 80-84.
194. Ackerstaff E, Glunde K, Bhujwalla ZM. Choline phospholipids metabolism: a target in cancer cells? Journal of Cellular Biochemistry 2003; 90: 525-533.
195. Roebuck JR, Cecil KM, Schnall MD, Lenkinski RE. Human breast lesions: characterization with proton MR spectroscopy. Radiology 1998; 209: 269-275.
196. Gribbestad IS, Singstad TE, Nilsen G, et al. In vivo H-1 MRS of normal breast and breast tumors using a dedicated double breast coil. J Magn Reson Imaging 1998; 8: 1191-1197.
197. Kvistad KA, Bakken IJ, Gribbestad IS, et al. Characterization of neoplastic and normal human breast tissues with in vivo (1)H MR spectroscopy. J Magn Reson Imaging 1999; 10: 159-164.
198. Yeung DK, Cheung HS, Tse GM. Human breast lesions: characterization with contrast-enhanced in vivo proton MR spectroscopy-initial results. Radiology 2001; 220: 40-46.
199. Jagannathan NR, Kumar M, Seenu V, et al. Evaluation of total choline from in-vivo volume localized proton MR spectroscopy and its response to neoadjuvant chemotherapy in locally advanced breast cancer. Br J Cancer 2001; 84: 1016-1022.
200. Thomas MA, Binesh N, Yue K, DeBruhl N. Volume-localized two-dimensional correlated magnetic resonance spectroscopy of human breast cancer. J Magn Reson Imaging 2001; 14: 181-186.
201. Cecil KM, Schnall MD, Siegelman ES, Lenkinski RE. The evaluation of human breast lesions with magnetic resonance imaging and proton magnetic resonance spectroscopy. Breast Cancer Res Treat 2001; 68: 45-54.
202. Katz-Brull R, Lavin PT, Lenkinski RE. Clinical utility of proton magnetic resonance spectros-copy in characterizing breast lesions. J. Natl. Cancer Inst. 2002; 94: 1197-1203.
203. 1H MRS of breast lesions." Magn Reson Med 2002; 48(2): 215-222.
204. Bolan PJ, Meisamy S, Baker EH, et al. "In vivo quantification of choline compounds in the breast with 1H MR spectroscopy." Magn Reson Med 2003; 50(6): 1134-1143.
205. 1H MR spectroscopy of human head and neck lymph node metastasis and comparison with oxygen tension measurements." Am J Neuroradiol 2000; 21(1): 183-93.
206. Gribbestad IS, Sitter B, Lundgren S, Krane J, Axelson D. Metabolite composition in breast tumors examined by proton nuclear magnetic resonance spectroscopy. Anticancer Res 1999; 19: 1737-1746.
207. Bartella L, Morris EA, Dershaw DD, et al. Proton MR spectroscopy with choline peak as malignancy marker improves positive predictive value for breast cancer diagnosis: preliminary study. Radiology 2006; 239: 686-692.
208. Huang W, Fisher PR, Khaldoon D, et al. Detection of malignancy: diagnostic MR protocol for improved specificity. Radiology 2004; 232: 585-591.
209. Yeung DK, Cheung HS, Tse GM. Breast cancer: in vivo proton MR spectroscopy in the characterization of histopathologic subtypes and preliminary observations in axillary node metas-tases. Radiology 2002; 225: 190-197.
210. 1H MR spectroscopy to improve diagnostic accuracy of breast MR imaging: preliminary results of observer performance study at 4.0 T. Radiology 2005; 236: 465-475.
211. 1H MR spectroscopy\a pilot study at 4 T. Radiology 2004; 233: 424-431.
212. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92:205-216.
213. Jacobs MA, Barker PB, Bottomley PA, et al. Proton magnetic resonance spectroscopic imaging of human breast cancer: a preliminary study. Journal of Magnetic Resonance Imaging 2004; 19: 68-75.
214. Medved M, Newstead GM, Abe H, et al. High spectral and spatial resolution MRI of breast lesions: preliminary clinical experience. Am. J. Roentgenol. 2006; 186: 30-37 and references therein.
215. 1 in homogeneity on breast MR imaging at 3.0 T. (Letters to the Editors) Radiology 2007; 244: 929-930.